Skip to main content

Table 3 Estimated cost-effectiveness thresholds

From: Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

 

Germany

United States

GDP per capita in $ in 2018

54,457

62,853

Factor

Cost-effectiveness thresholds in $/LY (QALY)

3

163,371

188,559

6

326,742

377,118

9

490,113

565,677

  1. GDP gross domestic product, LY life year, QALY quality-adjusted life year